Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD27+CD21+ B-cell and IgA plasmablast dynamics in IgA nephropathy patients treated with Nefecon
ChiCTR2500115491Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nefecon in IgA nephropathy (IgAN), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Percentage reduction in 24-hour proteinuria at 12 months versus baseline, Plasma galactose-deficient IgA1 and 3 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500115491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115491.